

residues 201-205 of the identical chain or an amino acid sequence starting between residues 79-110 of the MSP α chain (SEQ ID NO:20) and ending between residues 186-190 of the identical chain;

K2 comprises an amino acid sequence starting between residues 202-206 of HGF α chain (SEQ ID NO:18) and ending between residues 283-299 of the identical chain or an amino acid sequence starting between residues 187-191 of MSP α chain (SEQ ID NO:20) and ending between residues 268-282 of the identical chain;

m and n are 0 or 1;

B is the sequence $[(X)_q Y]_r$, wherein X = Gly and Y = Ser, or Cys, or Met, or Ala;

q is an integer from 2 to 8;

r is an integer from 1 to 9;

[C] corresponds to the sequence HL-K1-(K2)_s

wherein HL, K1, and K2 are as defined above,

s is 0 or 1;

D is the sequence W-Z, wherein W is a conventional proteolytic site, Z is any tag sequence useful for the purification and detection of the protein; and y is 0 or 1.

Claim 2. (Twice Amended) The recombinant protein according to claim 1, wherein:

HL comprises amino acids 32 to 127 of the HGF α chain (SEQ ID NO:18), or amino acids 19 to 98 of the MPS α chain (SEQ ID NO:20);

K1 comprises amino acids 128 to 203 of the HGF α chain (SEQ ID NO:18), or amino acids 99 to 188 of the MPS α chain (SEQ ID NO:20);
and

K2 comprises amino acids 204 to 294 of the HGF α chain (SEQ ID NO:18), or amino acids 189 to 274 of the MPS α chain (SEQ ID NO:20).

Claim 3. (Twice Amended) The recombinant protein according to claim 1 of formula (II):

c2
cont
$$LS_{MSP}-HL_{MSP}-K1_{MSP}-K2_{MSP}-L-HL_{HGF}-K1_{HGF}-K2_{HGF}-D \quad (II)$$

wherein LS_{MSP} comprises amino acids 1-18 of MSP (SEQ ID NO:20), HL_{MSP} comprises amino acids 19-56 of MSP (SEQ ID NO:20), $K1_{MSP}$ comprises amino acids 99-188 of MSP (SEQ ID NO:20), $K2_{MSP}$ comprises amino acids 189-274 of MSP, HL_{HGF} comprises amino acids 32-127 of HGF, $K1_{HGF}$ comprises amino acids 128-203 of HGF, $K2_{HGF}$ comprises amino acids 204-294 of HGF, L comprises the sequence $(Gly_4Ser)_3$, D comprises the sequence Asp_4-His_6 .

c3
Claim 10. (Twice Amended) A therapeutic agent comprising the recombinant protein of claim 1.

⁵
Claim ~~13~~. (Twice Amended) A pharmaceutical composition

C⁴ comprising an effective amount of the recombinant protein of claim
1 in combination with pharmacologically acceptable excipients.

Attached hereto is a marked up version showing the changes
made to the application by this Amendment.